about
Immune checkpoint blockade therapy for bladder cancer treatmentTrial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyMolecular mechanisms of cisplatin resistance in cervical cancerAntioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal ResultsPotential targets for ovarian clear cell carcinoma: a review of updates and future perspectivesTrial Watch: Adoptive cell transfer for oncological indicationsMitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer ChemotherapyDeciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineChloroquine and hydroxychloroquine for cancer therapySystems biology of cisplatin resistance: past, present and futureTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial Watch:: Oncolytic viruses for cancer therapyTargeting Hsp90 in urothelial carcinomaGlutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicTrial Watch-Oncolytic viruses and cancer therapyExploring the tumor microenvironment with nanoparticlesTrial Watch: Proteasomal inhibitors for anticancer therapyElevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaChip-based analysis of exosomal mRNA mediating drug resistance in glioblastomaCellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agentsFBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastomaTrial watch: Cardiac glycosides and cancer therapyDesign and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agentNorspermidine and novel Pd(II) and Pt(II) polynuclear complexes of norspermidine as potential antineoplastic agents against breast cancerKlotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathwayRad5 template switch pathway of DNA damage tolerance determines synergism between cisplatin and NSC109268 in Saccharomyces cerevisiaeIdentification of cisplatin-regulated metabolic pathways in pluripotent stem cellsExploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomasUpregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathwayEvolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancersWithaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cellsCisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian TumorsElevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer CellsmiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian CancerMolecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling.
P2860
Q26744139-BF7C1ED6-AD91-492B-89A8-E580885FC56DQ26745673-60BA6228-B5A5-4902-984E-4A15177CC5AEQ26745686-3AE13D6E-89C2-46BB-A1F5-18A2965D9636Q26746228-B5AFDF68-6F47-41A2-981D-443AA062E4FCQ26774897-BD38C768-1B04-4E23-AA01-82BA409A2AD6Q26775315-0C22A2C7-F34B-4C2F-90D9-B8DB1BA18F80Q26785545-54BE4D04-F284-4DB0-8A0C-04EE8CF95794Q26797353-3F02A7F5-8101-46FC-A0EE-0461943A4066Q26825186-3B325012-C088-46C6-ACFF-509715645F97Q26827797-8DCACF60-A665-4362-8BDE-92B69AE9F04FQ26863585-C47D893C-31B0-4E7E-91B4-F4A927EF4E05Q26993238-12795767-4362-4AA5-AFAF-0E1764FF5DFDQ27004011-260E3250-8851-491F-B2B1-E5A51027A4FDQ27021951-746F4B8F-6107-451C-9067-71836D4BAA1AQ27023406-4F3C06FA-BB13-4CB3-8483-E0C163760D70Q27853038-464794C5-6FE5-415D-80EF-8BC5906C1A5EQ27853206-B0819EE8-78BC-4BA2-B47D-B4FB8376C885Q28071541-3A5000E9-D739-4DF6-9C9A-1309E934F69CQ28072347-08AB138B-6BCA-4978-8A6D-1542CFC604A2Q28082374-80092759-9200-4928-8614-03FC1B3BA896Q28082910-52427991-28E7-473E-BBAD-4FACA38A27CFQ28084715-E5C1EAC3-AE11-43BF-AFFA-89ADED7D42F5Q28261810-73DD3A10-B754-43A4-8CED-64A23BF50106Q28383284-D4C7744B-FC69-4C9A-B6F0-CB6B2E851D63Q28391884-D80985D8-7B84-4D30-8C82-A6C7426376E4Q28395830-0E816DC9-564D-4DC4-BA93-E20B316BF26CQ28396437-822009F6-0506-4EEF-8EBB-BE6788F58D85Q28486150-BB73C4E1-8B44-4A7D-B930-A47BE0E3D0A6Q28486480-275DF6A5-2D03-4550-B5C1-2810FC192A50Q28534339-7A171FAE-1443-4922-AAED-5FDE6FCC09E5Q28534469-B52330C7-C6F6-488F-86E1-4D2075851395Q28538327-DD9AFAB0-BDF5-4577-BBC2-124667C0B19FQ28539122-1ECC6C4F-63B6-428E-BCAC-BF106B33E2B8Q28542563-4C215EC4-0BD0-4849-AA17-7578FA132C65Q28543359-08373882-5194-4679-9F41-1547EFF873CDQ28550863-02060E31-C0C8-4B9D-B9B0-01EC4E090F2AQ28553961-A95FCC10-A832-4558-A19D-56A290C4D6D0Q28606716-2DD907C4-FE5D-44C2-A5C7-2072E0856644Q28833833-A0AC2307-3008-4F8B-AEDE-867C32947A30Q30369661-64FCBAA7-A715-4137-9367-BEF4E4EB467B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular mechanisms of cisplatin resistance.
@en
Molecular mechanisms of cisplatin resistance.
@nl
type
label
Molecular mechanisms of cisplatin resistance.
@en
Molecular mechanisms of cisplatin resistance.
@nl
prefLabel
Molecular mechanisms of cisplatin resistance.
@en
Molecular mechanisms of cisplatin resistance.
@nl
P2093
P50
P356
P1433
P1476
Molecular mechanisms of cisplatin resistance.
@en
P2093
P2888
P304
P356
10.1038/ONC.2011.384
P407
P577
2011-09-05T00:00:00Z
P5875
P6179
1008798576